Editorial Comment to Survival beyond cabazitaxel for metastatic castration‐resistant prostate cancer
Yoshiyuki Yamamoto,
Norio Nonomura
Abstract:Phase III study comparing a reduced dose of cabazitaxel (20 mg/m 2 ) and the currently approved dose (25 mg/m 2 ) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA.
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.